NEW YORK (GenomeWeb) — Luminex reported after the close of the market Monday a 12 percent spike in third quarter revenues driven primarily by growth in assay sales across all major product categories.

The company also pushed back the commercialization timeline for Aries, its sample-to-answer molecular diagnostics system.

For the three months ended Sept. 30, the Austin, Texas-based molecular diagnostics firm tallied $56.7 million in revenues, compared to $50.8 million in the year-ago period, and edging the average analyst estimate of $56.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.